Phase 2 N=149 Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis
Severe Aortic Stenosis · Iron-deficiency
Primary: Submaximal Exercise Test — 375; 384 meters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=270 A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.
Haematopoiesis
Primary: Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily) — 2.6; 2.8 Gram per…
N/A N=23 Feasibility or Oral Lactoferrin to Prevent Iron Deficiency Anemia in Obese Pregnancy
Iron-deficiency · Pregnancy Anemia · Obesity
Primary: Recruitment Feasibility — 10 percentage eligible and enrolled
Phase 3 N=265 Vitamin D Status of Pregnant Women and Their Children in Eau Claire, South Carolina
Vitamin D Deficiency · Pregnancy
Primary: 25-hydroxyvitamin D at Visit 7 — 36.7; 39.8 ng/mL
Phase 2 N=1,050 Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age
Dengue Fever · Dengue Hemorrhagic Fever
Primary: STAGE-I: Geometric Mean Titers (GMTs) Against Each Dengue Virus Serotype 28 Days After Last CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline…
Phase 3 N=63 Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)
Primary Immune Deficiency Disorders (PIDD)
Primary: Rate of Serious Bacterial Infections (SBIs) Per Person-year on Treatment — 0.035 SBIs Per Total Person-Years
Phase 2 N=114 New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial
Diabetes Mellitus, Type 1
Primary: Mean Stimulated C-peptide Area Under the Curve — 0.28; 0.27; 0.25 pmol/ml — p=0.47
Phase 2 N=11 An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma
Melanoma
Primary: Number of Conversions of Non-inflamed to Inflamed Melanoma — 3; 7 Participants
N/A N=127 Iron Treatment for Young Children With Non-anemic Iron Deficiency
Non-anemic Iron Deficiency
Primary: Early Learning Composite (ELC) From the Mullen Scales of Early Learning — 113.0; 113.5; 110.48; 107.94 units on a scale
N/A N=308 COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Immunodeficiencies · Immune Dysregulations
Primary: Change in S and Receptor Binding Domain (RBD) Immunoglobulin G (IgG) Antibody Titer From Baseline Depending on Vaccine Manufacturer and Platform — 0.447333; 2.10678…
Phase 4 N=20 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia
Growth Hormone Deficiency · Septo-Optic Dysplasia · Hypopituitarism
Primary: Change in Anthropometric Measures Over Time — 1.97; -0.61; 1.39; 1.22 Z-score
N/A N=24 Mobile Motivational Physical Activity Targeted Intervention
Osteoarthritis
Primary: Mixed Effect Model Inferential Estimates of Longitudinal Changes Across 3 Time Points (Baseline, Week 14, Week 19) in Insomnia Severity Index — -1.24 units on a scale
Phase 2 N=44 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Neuroblastoma · Sarcoma · Rhabdomyosarcoma-Embryonal
Primary: Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay — 0; 15 Participants — p=0.043
Phase 4 N=183 Treatment Study of Vitamin D Deficiency in Adolescents
Vitamin D Deficiency
Primary: Change in 25(OH)D Serum Level After Treatment for Vitamin D Deficiency (Deficiency Defined as 25(OH)D <20 ng/dL) — 6.2; 24.9; 21 ng/mL
N/A N=43 Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression
Immunosuppression
Primary: Influenza Hemagluttination Inhibition Titers Measured Against H3N2 Perth Before and After Influenza Vaccination — 19; 5; 6 participants